2025年资本市场赛程过半,创新药板块以破竹之势,强势摘得“最亮眼赛道”桂冠。告别前几年的“牛夫人”时代,板块化身资金竞逐的“小甜甜”——截至8月19日,恒生港股通创新药精选指数年内飙升108.09%,刷新2018年以来的半年涨幅纪录。交银证券对此断言:2025年正成为医药行业从“估值修复”迈向“价值重估”的关键转折之年。这一转折恰逢其时。2025年,处于“十四五”收官与“十五五”启航的历史交汇点...
Source Link2025年资本市场赛程过半,创新药板块以破竹之势,强势摘得“最亮眼赛道”桂冠。告别前几年的“牛夫人”时代,板块化身资金竞逐的“小甜甜”——截至8月19日,恒生港股通创新药精选指数年内飙升108.09%,刷新2018年以来的半年涨幅纪录。交银证券对此断言:2025年正成为医药行业从“估值修复”迈向“价值重估”的关键转折之年。这一转折恰逢其时。2025年,处于“十四五”收官与“十五五”启航的历史交汇点...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.